Current strategies in gene therapy for ovarian cancer

Current Opinion in Obstetrics and Gynecology

Volumn 13, Issue 1, 2001, Pages 47-51

  Barnes, Mack N ^a   Pustilnik, Terri B ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ADENOVIRUS; CARCINOGENESIS; DNA MODIFICATION; DNA VECTOR; GENE TARGETING; GENE THERAPY; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; REVIEW;

CLINICAL TRIALS; FEMALE; GENE THERAPY; HUMANS; OVARIAN NEOPLASMS;

EID: 0034920402     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200102000-00007     Document Type: Review

References (38)

1. Gene therapy and ovarian cancer: A review
2. Immunoglobulin in ovarian cancer ascites inhibits viral infection: Implications for adenoviral mediated gene therapy
3. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: Evidence for reduced toxicity and enhanced anti-tumor activity in mice
4. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches
5. A genetically targeted adenoviral vector for suicide gene therapy for ovarian carcinoma
6. Gene therapy: Promises, problems, and prospects
7. Stable and efficient gene transfer into the retina using an HIV based lentiviral vector
8. Adeno-associated viral vectors for gene transfer and gene therapy
9. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab' gamma) 2 antibody
10. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells
11. Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer gene therapy
12. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy
13. Nonviral gene therapy: Promises and challenges
14. A novel N-acyl phosphatidylethanolamine-containing delivery vehicle for spermine condensed plasmid DNA
15. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy
16. Ovarian cancer gene therapy: Repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine model
17. Comparison of long-term survival of cytomegalovirus promoter versus Rous Sarcoma virus promoter driven thymidine kinase gene therapy in nude mice bearing human ovarian cancer
18. Efficacy of adenovirus mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concominant with p53 gene therapy
19. Adenovirus mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status
20. In vivo studies of adenovirus-mediated p53 gene therapy for cisplatin resistant human ovarian tumor xenografts
21. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer
22. Growth suppression of human ovarian cancer cells by adenovirus mediated transfer of the PTEN gene
23. Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus
24. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene
25. An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancer
26. Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment
27. E1A mediated paclitaxel sensitization in HER-2/neu over-expressing ovarian cancer SKOV-3.ip1 through apoptosis involving the caspase-3 pathway
28. Genetic immunotherapy for cancer
29. Gene-modified dendritic cells for use in tumor vaccines
30. Immunotherapy of cancer using interleukin-2: Current status and future prospects
31. Immunological properties of tumor cells genetically modified to secrete interleukin-2
32. Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvic
33. Maturation of dendritic cells (DC) from ovarian cancer patients
34. Vaccine therapy for ovarian cancer using herpes simplex virus thymidine kinase (HSV-TK) suicide gene transfer technique: A phase I study
35. LTKOSN.1 Murine vector producer cell (VPC) for the in vivo delivery of the herpes simplex thymidine kinase (HSVTK) gene for ovarian cancer
36. Adenoviral mediated suicide gene therapy for ovarian cancer
37. A Phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer
38. A Phase I/II trial of recombinant adenoviral human p53 intraperitoneal gene therapy in recurrent ovarian cancer